Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' RIENDEAU D' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 60 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Chauret, N; Yergey, JA; Brideau, C; Friesen, RW; Mancini, J; Riendeau, D; Silva, J; Styhler, A; Trimble, LA; Nicoll-Griffith, DA
      In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663)

      BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
    2. Guan, YF; Zhang, YH; Schneider, A; Riendeau, D; Mancini, JA; Davis, L; Komhoff, M; Breyer, RM; Breyer, MD
      Urogenital distribution of a mouse membrane-associated prostaglandin E-2 synthase

      AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY
    3. Ouellet, M; Riendeau, D; Percival, MD
      A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin

      PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
    4. Riendeau, D; Percival, MD; Brideau, C; Charleson, S; Dube, D; Ethier, D; Falgueyret, JP; Friesen, RW; Gordon, R; Greig, G; Guay, J; Mancini, J; Ouellet, M; Wong, E; Xu, L; Boyce, S; Visco, D; Girard, Y; Prasit, P; Zamboni, R; Rodger, IW; Gresser, M; Ford-Hutchinson, AW; Young, RN; Chan, CC
      Etoricoxib (MK-0663): Preclinical profile and comparison with other agentsthat selectively inhibit cyclooxygenase-2

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    5. Falgueyret, JP; Oballa, RM; Okamoto, O; Wesolowski, G; Aubin, Y; Rydzewski, RM; Prasit, P; Riendeau, D; Rodan, SB; Percival, MD
      Novel, nonpeptidic cyanamides as potent and reversible inhibitors of humancathepsins K and L

      JOURNAL OF MEDICINAL CHEMISTRY
    6. Mancini, JA; Blood, K; Guay, J; Gordon, R; Claveau, D; Chan, CC; Riendeau, D
      Cloning, expression, and up-regulation of inducible rat prostaglandin E synthase during lipopolysaccharide-induced pyresis and adjuvant-induced arthritis

      JOURNAL OF BIOLOGICAL CHEMISTRY
    7. Wong, E; Huang, JQ; Tagari, P; Riendeau, D
      Effects of COX-2 inhibitors on aortic prostacyclin production in cholesterol-fed rabbits

      ATHEROSCLEROSIS
    8. Claveau, D; Riendeau, D
      Mutations of the C-terminal end of cathepsin K affect proenzyme secretion and intracellular maturation

      BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
    9. Falgueyret, JP; Riendeau, D
      LTA(4)-derived 5-oxo-eicosatetraenoic acid: pH-dependent formation and interaction with the LTB4 receptor of human polymorphonuclear leukocytes

      BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
    10. Nicoll-Griffith, DA; Yergey, JA; Trimble, LA; Silva, JM; Li, C; Chauret, N; Gauthier, JY; Grimm, E; Leger, S; Roy, P; Therien, M; Wang, ZY; Prasit, P; Zamboni, R; Young, RN; Brideau, C; Chan, CC; Mancini, J; Riendeau, D
      Synthesis, characterization, and activity of metabolites derived from the cyclooxygenase-2 inhibitor rofecoxib (MK-0966, Vioxx (TM))

      BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
    11. Claveau, D; Riendeau, D; Mancini, JA
      Expression, maturation, and rhodamine-based fluorescence assay of human cathepsin K expressed in CHO cells

      BIOCHEMICAL PHARMACOLOGY
    12. Guay, J; Riendeau, D; Mancini, JA
      Cloning and expression of rhesus monkey cathepsin K

      BONE
    13. Li, CS; Black, WC; Brideau, C; Chan, CC; Charleson, S; Cromlish, WA; Claveau, D; Gauthier, JY; Gordon, R; Greig, G; Grimm, E; Guay, J; Lau, CK; Riendeau, D; Therien, M; Visco, DM; Wong, E; Xu, LJ; Prasit, P
      A new structural variation on the methanesulfonylphenyl class of selectivecyclooxygenase-2 inhibitors

      BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
    14. Lau, CK; Brideau, C; Chan, CC; Charleson, S; Cromlish, WA; Ethier, D; Gauthier, JY; Gordon, R; Guay, J; Kargman, S; Li, CS; Prasit, P; Riendeau, D; Therien, M; Visco, DM; Xu, LJ
      Synthesis and biological evaluation of 3-heteroarizoxy-4-phenyl-2(5H)-furanones as selective COX-2 inhibitors

      BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
    15. Ouimet, N; Chan, CC; Charleson, S; Claveau, D; Gordon, R; Guay, D; Li, CS; Ouellet, M; Percival, DM; Riendeau, D; Wong, E; Zamboni, R; Prasit, P
      Substituted heterocyclic analogs as selective COX-2 inhibitors in the Flosulide class

      BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
    16. Frenette, R; Hutchinson, JH; Leger, S; Therien, M; Brideau, C; Chan, CC; Charleson, S; Ethier, D; Guay, J; Jones, TR; McAuliffe, M; Piechuta, H; Riendeau, D; Tagari, P; Girard, Y
      Substituted indoles as potent and orally active 5-lipoxygenase activating protein (FLAP) inhibitors

      BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
    17. Leblanc, Y; Roy, P; Boyce, S; Brideau, C; Chan, CC; Charleson, S; Gordon, R; Grimm, E; Guay, J; Leger, S; Li, CS; Riendeau, D; Visco, D; Wang, Z; Webb, J; Xu, LJ; Prasit, P
      Sar in the alkoxy lactone series: The discovery of DFP, a potent and orally active COX-2 inhibitor

      BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
    18. Prasit, P; Wang, Z; Brideau, C; Chan, CC; Charleson, S; Cromlish, W; Ethier, D; Evans, JF; Ford-Hutchinson, AW; Gauthier, JY; Gordon, R; Guay, J; Gresser, M; Kargman, S; Kennedy, B; Leblanc, Y; Leger, S; Mancini, J; O'Neill, GP; Ouellet, M; Percival, MD; Perrier, H; Riendeau, D; Rodger, I; Tagari, P; Therien, M; Vickers, P; Wong, E; Xu, LJ; Young, RN; Zamboni, R; Boyce, S; Rupniak, N; Forrest, N; Visco, D; Patrick, D
      The discovery of rofecoxib, [MK 966, Vioxx (R), 4-(4 '-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor

      BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
    19. Dube, D; Brideau, C; Deschenes, D; Fortin, R; Friesen, RW; Gordon, R; Girard, Y; Riendeau, D; Savoie, C; Chan, CC
      2-heterosubstituted-3-(4-methylsulfonyl)phenyl-5-trifluoromethyl pyridinesas selective and orally active cyclooxygenase-2 inhibitors

      BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
    20. Nicoll-Griffith, DA; Falgueyret, JP; Silva, JM; Morin, PE; Trimble, L; Chan, CC; Clas, S; Leger, S; Wang, ZY; Yergey, JA; Riendeau, D
      Oxidative bioactivation of the lactol prodrug of a lactone cyclooxygenase-2 inhibitor

      DRUG METABOLISM AND DISPOSITION
    21. Chan, CC; Boyce, S; Brideau, C; Charleson, S; Cromlish, W; Ethier, D; Evans, J; Ford-Hutchinson, AW; Forrest, MJ; Gauthier, JY; Gordon, R; Gresser, M; Guay, J; Kargman, S; Kennedy, B; Leblanc, Y; Leger, S; Mancini, J; O'Neill, GP; Ouellet, M; Patrick, D; Percival, MD; Perrier, H; Prasit, P; Rodger, I; Tagari, P; Therien, M; Vickers, P; Visco, D; Wang, Z; Webb, J; Wong, E; Xu, LJ; Young, RN; Zamboni, R; Riendeau, D
      Rofecoxib [Vioxx, MK-0966; 4-(4 '-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: A potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    22. Black, WC; Brideau, C; Chan, CC; Charleson, S; Chauret, N; Claveau, D; Ethier, D; Gordon, R; Greig, G; Guay, J; Hughes, G; Jolicoeur, P; Leblanc, Y; Nicoll-Griffith, D; Ouimet, N; Riendeau, D; Visco, D; Wang, ZY; Xu, L; Prasit, P
      2,3-diarylcyclopentenones as orally active, highly selective cyclooxygenase-2 inhibitors

      JOURNAL OF MEDICINAL CHEMISTRY
    23. Denis, D; Riendeau, D
      Phosphodiesterase 4-dependent regulation of cyclic AMP levels and leukotriene B-4 biosynthesis in human polymorphonuclear leukocytes

      EUROPEAN JOURNAL OF PHARMACOLOGY
    24. Ehrich, EW; Dallob, A; De Lepeleire, I; Van Hecken, A; Riendeau, D; Yuan, WY; Porras, A; Wittreich, J; Seibold, JR; De Schepper, P; Mehlisch, DR; Gertz, BJ
      Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    25. FRIESEN RW; BRIDEAU C; CHAN CC; CHARLESON S; DESCHENES D; DUBE D; ETHIER D; FORTIN R; GAUTHIER JY; GIRARD Y; GORDON R; GREIG GM; RIENDEAU D; SAVOIE C; WANG ZY; WONG E; VISCO D; XU LJ; YOUNG RN
      2-PYRIDINYL-3-(4-METHYLSULFONYL)PHENYLPYRIDINES - SELECTIVE AND ORALLY-ACTIVE CYCLOOXYGENASE-2 INHIBITORS

      Bioorganic & medicinal chemistry letters
    26. DUBE D; BLOUIN M; BRIDEAU C; CHAN CC; DESMARAIS S; ETHIER D; FALGUEYRET JP; FRIESEN RW; GIRARD M; GIRARD Y; GUAY J; RIENDEAU D; TAGARI P; YOUNG RN
      QUINOLINES AS POTENT 5-LIPOXYGENASE INHIBITORS - SYNTHESIS AND BIOLOGICAL PROFILE OF L-746,530

      Bioorganic & medicinal chemistry letters
    27. Mancini, JA; Waterman, H; Riendeau, D
      Cellular oxygenation of 12-hydroxyeicosatetraenoic acid and 15-hydroxyeicosatetraenoic acid by 5-lipoxygenase is stimulated by 5-lipoxygenase-activating protein

      JOURNAL OF BIOLOGICAL CHEMISTRY
    28. WONG E; DELUCA C; BOILY C; CHARLESON S; CROMLISH W; DENIS D; KARGMAN S; KENNEDY BP; OUELLET M; SKOREY K; ONEILL GP; VICKERS PJ; RIENDEAU D
      CHARACTERIZATION OF AUTOCRINE INDUCIBLE PROSTAGLANDIN-H SYNTHASE-2 (PGHS-2) IN HUMAN OSTEOSARCOMA CELLS

      Inflammation research
    29. THERIEN M; BRIDEAU C; CHAN CC; CROMLISH WA; GAUTHIER JY; GORDON R; GREIG G; KARGMAN S; LAU CK; LEBLANC Y; LI CS; ONEILL GP; RIENDEAU D; ROY P; WANG ZY; XU LJ; PRASIT P
      SYNTHESIS AND BIOLOGICAL EVALUATION OF 5,6-DIARYLIMIDAZO[2.1-B]THIAZOLE AS SELECTIVE COX-2 INHIBITORS

      Bioorganic & medicinal chemistry letters
    30. MANCINI JA; VICKERS PJ; ONEILL GP; BOILY C; FALGUEYRET JP; RIENDEAU D
      ALTERED SENSITIVITY OF ASPIRIN-ACETYLATED PROSTAGLANDIN G H SYNTHASE-2 TO INHIBITION BY NONSTEROIDAL ANTIINFLAMMATORY DRUGS/

      Molecular pharmacology
    31. HAMEL P; RIENDEAU D; BRIDEAU C; CHAN CC; DESMARAIS S; DELORME D; DUBE D; DUCHARME Y; ETHIER D; GRIMM E; FALGUEYRET JP; GUAY J; JONES TR; KWONG E; MCAULIFFE M; MCFARLANE CS; PIECHUTA H; ROUMI M; TAGARI P; YOUNG RN; GIRARD Y
      SUBSTITUTED (PYRIDYLMETHOXY)NAPHTHALENES AS POTENT AND ORALLY-ACTIVE 5-LIPOXYGENASE INHIBITORS - SYNTHESIS, BIOLOGICAL PROFILE, AND PHARMACOKINETICS OF L-739,010

      Journal of medicinal chemistry
    32. JAKOBSSON PJ; MANCINI JA; RIENDEAU D; FORDHUTCHINSON AW
      IDENTIFICATION AND CHARACTERIZATION OF A NOVEL MICROSOMAL-ENZYME WITHGLUTATHIONE-DEPENDENT TRANSFERASE AND PEROXIDASE-ACTIVITIES

      The Journal of biological chemistry
    33. WONG E; BAYLY C; WATERMAN HL; RIENDEAU D; MANCINI JA
      CONVERSION OF PROSTAGLANDIN G H SYNTHASE-1 INTO AN ENZYME SENSITIVE TO PGHS-2-SELECTIVE INHIBITORS BY A DOUBLE HIS(513)-]ARG AND ILE(523)-]VAL MUTATION/

      The Journal of biological chemistry
    34. RIENDEAU D; CHARLESON S; CROMLISH W; MANCINI JA; WONG E; GUAY J
      COMPARISON OF THE CYCLOOXYGENASE-1 INHIBITORY PROPERTIES OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS (NSAIDS) AND SELECTIVE COX-2 INHIBITORS, USING SENSITIVE MICROSOMAL AND PLATELET ASSAYS

      Canadian journal of physiology and pharmacology
    35. RIENDEAU D; PERCIVAL MD; BOYCE S; BRIDEAU C; CHARLESON S; CROMLISH W; ETHIER D; EVANS J; FALGUEYRET JP; FORDHUTCHINSON AW; GORDON R; GREIG G; GRESSER M; GUAY J; KARGMAN S; LEGER S; MANCINI JA; ONEILL G; OUELLET M; RODGER IW; THERIEN M; WANG Z; WEBB JK; WONG E; XU L; YOUNG RN; ZAMBONI R; PRASIT P; CHAN CC
      BIOCHEMICAL AND PHARMACOLOGICAL PROFILE OF A TETRASUBSTITUTED FURANONE AS A HIGHLY SELECTIVE COX-2 INHIBITOR

      British Journal of Pharmacology
    36. FRIESEN RW; DUBE D; FORTIN R; FRENETTE R; PRESCOTT S; CROMLISH W; GREIG GM; KARGMAN S; WONG E; CHAN CC; GORDON R; XU LJ; RIENDEAU D
      NOVEL 1,2-DIARYLCYCLOBUTENES - SELECTIVE AND ORALLY-ACTIVE COX-2 INHIBITORS

      Bioorganic & medicinal chemistry letters
    37. GAUTHIER JY; LEBLANC Y; BLACK WC; CHAN CC; CROMLISH WA; GORDON R; KENNEDEY BP; LAU CK; LEGER S; WANG ZY; ETHIER D; GUAY J; MANCINI J; RIENDEAU D; TAGARI P; VICKERS P; WONG E; XU LJ; PRASIT P
      SYNTHESIS AND BIOLOGICAL EVALUATION OF 2,3-DIARYLTHIOPHENES AS SELECTIVE COX-2 INHIBITORS .2. REPLACING THE HETEROCYCLE

      Bioorganic & medicinal chemistry letters
    38. MANCINI JA; ONEILL GP; FALGUEYRET JP; VICKERS PJ; RIENDEAU D
      EFFECT OF MUTAGENESIS OF ARGININE-120 OF PGHS-1 AND ACETYLATION OF PGHS-2 ON THE INHIBITION OF NSAIDS

      The FASEB journal
    39. DELORME D; DUCHARME Y; BRIDEAU C; CHAN CC; CHAURET N; DESMARAIS S; DUBE D; FALGUEYRET JP; FORTIN R; GUAY J; HAMEL P; JONES TR; LEPINE C; LI C; MCAULIFFE M; MCFARLANE CS; NICOLLGRIFFITH DA; RIENDEAU D; YERGEY JA; GIRARD Y
      DIOXALBICYCLOOCTANYL NAPHTHALENENITRILES AS NONREDOX 5-LIPOXYGENASE INHIBITORS - STRUCTURE-ACTIVITY RELATIONSHIP STUDY DIRECTED TOWARD THE IMPROVEMENT OF METABOLIC STABILITY

      Journal of medicinal chemistry
    40. KARGMAN S; CHARLESON S; CARTWRIGHT M; FRANK J; RIENDEAU D; MANCINI J; EVANS J; ONEILL G
      CHARACTERIZATION OF PROSTAGLANDIN G H SYNTHASE-1 AND SYNTHASE-2 IN RAT, DOG, MONKEY, AND HUMAN GASTROINTESTINAL TRACTS/

      Gastroenterology
    41. DECAROLIS E; DENIS D; RIENDEAU D
      OXIDATIVE INACTIVATION OF HUMAN 5-LIPOXYGENASE IN PHOSPHATIDYLCHOLINEVESICLES

      European journal of biochemistry
    42. KARGMAN S; WONG E; GREIG GM; FALGUEYRET JP; CROMLISH W; ETHIER D; YERGEY JA; RIENDEAU D; EVANS JF; KENNEDY B; TAGARI P; FRANCIS DA; ONEILL GP
      MECHANISM OF SELECTIVE-INHIBITION OF HUMAN PROSTAGLANDIN G H SYNTHASE-1 AND SYNTHASE-2 IN INTACT-CELLS/

      Biochemical pharmacology
    43. LEBLANC Y; GAUTHIER JY; ETHIER D; GUAY J; MANCINI J; RIENDEAU D; TAGARI P; VICKERS P; WONG E; PRASIT P
      SYNTHESIS AND BIOLOGICAL EVALUATION OF 2,3-DIARYLTHIOPHENES AS SELECTIVE COX-2 AND COX-1 INHIBITORS

      Bioorganic & medicinal chemistry letters
    44. DECAROLIS E; RIENDEAU D
      INVESTIGATION OF THE MECHANISM INVOLVED IN THE INACTIVATION OF PURIFIED HUMAN 5-LIPOXYGENASE

      The FASEB journal
    45. MANCINI J; ONEILL G; KARGMAN S; BAYLY C; RIENDEAU D; VICKERS P
      ACTIVE-SITE MUTANTS OF HUMAN PROSTAGLANDIN G H SYNTHASE/

      The FASEB journal
    46. CHAN CC; BOYCE S; BRIDEAU C; FORDHUTCHINSON AW; GORDON R; GUAY D; HILL RG; LI CS; MANCINI J; PENNETON M; PRASIT P; RASORI R; RIENDEAU D; ROY P; TAGARI P; VICKERS P; WONG E; RODGER IW
      PHARMACOLOGY OF A SELECTIVE CYCLOOXYGENASE-2 INHIBITOR, L-745,337 - ANOVEL NONSTEROIDAL ANTIINFLAMMATORY AGENT WITH AN ULCEROGENIC SPARINGEFFECT IN RAT AND NONHUMAN PRIMATE STOMACH

      The Journal of pharmacology and experimental therapeutics
    47. HUTCHINSON JH; CHARLESON S; EVANS JF; FALGUEYRET JP; HOOGSTEEN K; JONES TR; KARGMAN S; MACDONALD D; MCFARLANE CS; NICHOLSON DW; PIECHUTA H; RIENDEAU D; SCHEIGETZ J; THERIEN M; GIRARD Y
      THIOPYRANOL[2,3,4-C,D] INDOLES AS INHIBITORS OF 5-LIPOXYGENASE, 5-LIPOXYGENASE-ACTIVATING PROTEIN, AND LEUKOTRIENE C-4 SYNTHASE

      Journal of medicinal chemistry
    48. MANCINI JA; RIENDEAU D; FALGUEYRET JP; VICKERS PJ; ONEILL GP
      ARGININE-120 OF PROSTAGLANDIN G H SYNTHASE-1 IS REQUIRED FOR THE INHIBITION BY NONSTEROIDAL ANTIINFLAMMATORY DRUGS CONTAINING A CARBOXYLIC-ACID MOIETY/

      The Journal of biological chemistry
    49. CHARETTE L; MISQUITTA C; GUAY J; RIENDEAU D; JONES TR
      INVOLVEMENT OF CYCLOOXYGENASE 2 (COX-2) IN INTRINSIC TONE OF ISOLATEDGUINEA-PIG TRACHEA

      Canadian journal of physiology and pharmacology
    50. FALGUEYRET JP; DENIS D; MACDONALD D; HUTCHINSON JH; RIENDEAU D
      CHARACTERIZATION OF THE ARACHIDONATE AND ATP BINDING-SITES OF HUMAN 5-LIPOXYGENASE USING PHOTOAFFINITY-LABELING AND ENZYME IMMOBILIZATION

      Biochemistry
    51. HUTCHINSON JH; RIENDEAU D; BRIDEAU C; CHAN C; FALGUEYRET JP; GUAY J; JONES TR; LEPINE C; MACDONALD D; MCFARLANE CS; PIECHUTA H; SCHEIGETZ J; TAGARI P; THERIEN M; GIRARD Y
      THIOPYRANO[2,3,4-CD]INDOLES AS 5-LIPOXYGENASE INHIBITORS - SYNTHESIS,BIOLOGICAL PROFILE, AND RESOLUTION OF RO-1H-THIOPYRANO[2,3,4-CD]INDOL-YL]ETHOXY]BUTANOIC ACID

      Journal of medicinal chemistry
    52. DUCHARME Y; BRIDEAU C; DUBE D; CHAN CC; FALGUEYRET JP; GILLARD JW; GUAY J; HUTCHINSON JH; MCFARLANE CS; RIENDEAU D; SCHEIGETZ J; GIRARD Y
      NAPHTHALENIC LIGNAN LACTONES AS SELECTIVE, NONREDOX 5-LIPOXYGENASE INHIBITORS - SYNTHESIS AND BIOLOGICAL-ACTIVITY OF (METHOXYALKYL)THIAZOLEAND METHOXYTETRAHYDROPYRAN HYBRIDS

      Journal of medicinal chemistry
    53. RIENDEAU D; GUAY J; WEECH PK; LALIBERTE F; YERGEY J; LI C; DESMARAIS S; PERRIER H; LIU S; NICOLLGRIFFITH D; STREET IP
      ARACHIDONYL TRIFLUOROMETHYL KETONE, A POTENT INHIBITOR OF 85-KDA PHOSPHOLIPASE A(2), BLOCKS PRODUCTION OF ARACHIDONATE AND 12-HYDROXYEICOSATETRAENOIC ACID BY CALCIUM IONOPHORE-CHALLENGED PLATELETS

      The Journal of biological chemistry
    54. DESMARAIS SR; RIENDEAU D; GRESSER MJ
      INHIBITION OF SOYBEAN LIPOXYGENASE-1 BY A DIARYL-N-HYDROXYUREA BY REDUCTION OF THE FERRIC ENZYME

      Biochemistry
    55. THERIEN M; FITZSIMMONS BJ; SCHEIGETZ J; MACDONALD D; CHOO LY; GUAY J; FALGUEYRET JP; RIENDEAU D
      JUSTICIDIN-E - A NEW LEUKOTRIENE BIOSYNTHESIS INHIBITOR

      Bioorganic & medicinal chemistry letters
    56. RIENDEAU D; FALGUEYRET JP; MEISNER D; SHERMAN MM; LALIBERTE F; STREET IP
      INTERFACIAL CATALYSIS AND PRODUCTION OF A HIGH RATIO OF LEUKOTRIENE-A(4) TO 5-HPETE BY 5-LIPOXYGENASE IN A COUPLED ASSAY WITH PHOSPHOLIPASE-A(2)

      Journal of lipid mediators
    57. PRASIT P; BELLEY M; BLOUIN M; BRIDEAU C; CHAN C; CHARLESON S; EVANS JF; FRENETTE R; GAUTHIER JY; GUAY J; GILLARD JW; GRIMM E; FORDHUTCHINSON AW; HUTCHINSON JH; FORTIN R; JONES TR; MANCINI J; LEGER S; MCFARLANE CS; PIECHUTA H; RIENDEAU D; ROY P; TAGARI P; VICKERS PJ; YOUNG RN; ZAMBONI R
      A NEW CLASS OF LEUKOTRIENE BIOSYNTHESIS INHIBITOR - THE DEVELOPMENT OF MK-0591

      Journal of lipid mediators
    58. HUTCHINSON JH; RIENDEAU D; BRIDEAU C; CHAN C; DELORME D; DENIS D; FALGUEYRET JP; FORTIN R; GUAY J; HAMEL P; JONES TR; MACDONALD D; MCFARLANE CS; PIECHUTA H; SCHEIGETZ J; TAGARI P; THERIEN M; GIRARD Y
      SUBSTITUTED THIOPYRANO[2,3,4-C,D]INDOLES AS POTENT, SELECTIVE, AND ORALLY-ACTIVE INHIBITORS OF 5-LIPOXYGENASE - SYNTHESIS AND BIOLOGICAL EVALUATION OF L-691,816

      Journal of medicinal chemistry
    59. CHASTEEN ND; GRADY JK; SKOREY KI; NEDEN KJ; RIENDEAU D; PERCIVAL MD
      CHARACTERIZATION OF THE NONHEME IRON CENTER OF HUMAN 5-LIPOXYGENASE BY ELECTRON-PARAMAGNETIC-RESONANCE, FLUORESCENCE, AND ULTRAVIOLET-VISIBLE SPECTROSCOPY - REDOX CYCLING BETWEEN FERROUS AND FERRIC STATES

      Biochemistry
    60. GRAVEL J; FALGUEYRET JP; YERGEY J; TRIMBLE L; RIENDEAU D
      IDENTIFICATION OF 5-KETO-(7E,9E,11Z,14Z)-EICOSATETRAENOIC ACID AS A NOVEL NONENZYMATIC REARRANGEMENT PRODUCT OF LEUKOTRIENE-A(4)

      Archives of biochemistry and biophysics


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 24/10/20 alle ore 02:55:37